Article thumbnail
Location of Repository

Use of cytoplasmic 5'nucleotidase for differentiating malignant from benign monoclonal gammopathies.

By G Majumdar, S E Heard and A K Singh

Abstract

Bone marrow smears from 15 patients with multiple myeloma, 15 patients with monoclonal gammopathy of undetermined significance (MGUS), and 15 control subjects were examined for the presence of cytoplasmic 5'nucleotidase (c5NT) in plasma cells. Plasma cell positivity for c5NT (mean and 95% confidence interval) in patients with multiple myeloma numbered 46.4% (38.0-54.8%), in those with MGUS it was 15.3% (11.1-19.6%), and in control subjects it was 1.2% (0.3-2.1%). These findings indicate that c5NT can be used to differentiate benign from malignant monoclonal gammopathies

Topics: Research Article
Year: 1990
DOI identifier: 10.1136/jcp.43.11.891
OAI identifier: oai:pubmedcentral.nih.gov:502896
Provided by: PubMed Central
Sorry, our data provider has not provided any external links therefore we are unable to provide a link to the full text.

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.